Over time, lower protein intake may affect muscle maintenance, recovery, strength, and overall daily energy
Nat Rev Endocrinol (2011) 8(3):16071
Medicaid to stop covering weight-loss drugs for obesity in New Hampshire The Alliance for Womens Health and Prevention, in support of coverage for weight-loss drugs, said obesity is associated with over 200 health complications
This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)
Many individuals can resume modified activity during mid-phase, with progressive loading helping direct tissue remodeling along functional lines
Peng S, Xu J, Ruan W, Li S, Xiao F